<DOC>
	<DOCNO>NCT00337259</DOCNO>
	<brief_summary>Marginal zone lymphoma , one indolent lymphoma , believe incurable chemotherapy . Thus investigator need novel agent marginal zone lymphoma . Gemcitabine try one salvage chemotherapy regimen show anti-lymphoma activity . To investigator ' knowledge , trial gemcitabine marginal zone lymphoma . Thus investigator make plan investigate role gemcitabine marginal zone lymphoma .</brief_summary>
	<brief_title>Gemcitabine Marginal Zone Lymphoma</brief_title>
	<detailed_description>We design multi-center phase II trial gemcitabine advance stage marginal zone B-cell lymphoma . Marginal zone lymphoma need novel agent improve clinical course chemotherapy . Recent trial new agent indolent lymphoma show promise result . Gemcitabine known activity non-Hodgkin 's lymphoma le adverse effect new agent . With background gemcitabine try single agent advance marginal zone lymphoma . Gemcitabine administer 1,250mg/sq.m day 1 8 every 3 week . Response assess IWC criterion .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically confirm marginal zone Bcell lymphoma Performance status ( ECOG ) ≤3 Age ≥ 18 At least one bidimensionally measurable lesion ( ) : 2 cm conventional CT 1 cm spiral CT skin lesion ( photograph take ) measurable lesion physical examination Laboratory value : Cr &lt; 2.0 mg % Ccr &gt; 60 ml/min Transaminase &lt; 3 X upper normal value Bilirubin &lt; 2 mg % ANC &gt; 1500/ul , platelet &gt; 75,000/ul Informed consent Ann Arbor stage III IV Any malignancy within past 5 year except skin basal cell ca CIS cervix Serious comorbid diseases Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>gemcitabine</keyword>
</DOC>